Vericel (VCEL) Set to Release Earnings on Thursday

Vericel (NASDAQ:VCEL) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Vericel to announce earnings of $0.0575 per share and revenue of $77.95 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Vericel Price Performance

Shares of Vericel stock opened at $40.51 on Tuesday. Vericel has a 1 year low of $28.95 and a 1 year high of $49.32. The company has a market capitalization of $2.07 billion, a P/E ratio of 86.23 and a beta of 1.02. The business has a 50 day moving average price of $40.54 and a 200 day moving average price of $38.68.

Analysts Set New Price Targets

Several research firms have weighed in on VCEL. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Vericel in a research report on Tuesday, July 28th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Truist Financial decreased their price objective on Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. TD Cowen lifted their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research note on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.20.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.